Late paradoxical lymph node enlargement during and after anti-tuberculosis treatment in non-HIV-infected patients

Int J Tuberc Lung Dis. 2015 Nov;19(11):1388-94. doi: 10.5588/ijtld.15.0257.

Abstract

Settings: A tertiary referral centre in South Korea.

Objective: To investigate the incidence, clinical characteristics and outcomes of late paradoxical response (>4 months after the initiation of anti-tuberculosis treatment) during and after anti-tuberculosis treatment in non-human immunodeficiency virus (HIV) infected patients with lymph node tuberculosis (TB).

Design: We retrospectively reviewed the medical records of non-HIV-infected patients with lymph node TB between 1997 and 2007, and prospectively enrolled patients with newly diagnosed lymph node TB between 2008 and 2013.

Results: Of 467 patients with confirmed and probable lymph node TB, 83 (18%) displayed a paradoxical response: 57 of these (69%) were classified as early and 26 (31%) as late paradoxical response. Patients with late paradoxical response (median 12 months) received more prolonged anti-tuberculosis treatment than those with early (median 9 months, P < 0.001) or no paradoxical response (median 9 months, P < 0.001). The frequency of post-treatment lymph node enlargement increased progressively from those without any paradoxical response (6%), through those with an early response (12%) to those with a late response (23%).

Conclusions: Paradoxical response presents late in about one third of non-HIV-infected patients with lymph node TB who experience a response. Although anti-tuberculosis treatment is commonly prolonged in patients with late paradoxical response, post-treatment lymph node enlargement is more frequent in these patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use*
  • Female
  • HIV Seronegativity*
  • Humans
  • Lymph Nodes / pathology*
  • Male
  • Middle Aged
  • Prospective Studies
  • Republic of Korea
  • Retrospective Studies
  • Tertiary Care Centers
  • Treatment Failure
  • Tuberculosis, Lymph Node / drug therapy*

Substances

  • Antitubercular Agents